Cary Street Partners Investment Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13	Closed	-$2.3K	–	679
2023 Q3	$2.3K	Hold	13	–	–	﹤0.01%	1637
2023 Q2	$2.47K	Hold	13	–	–	﹤0.01%	1560
2023 Q1	$2.6K	Hold	13	–	–	﹤0.01%	1462
2022 Q4	$3.09K	Buy	+13	New	+$2.77K	﹤0.01%	1430

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Cary Street Partners Investment Advisory's ALNY Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 13 shares — an estimated $2.3K sold.

Cary Street Partners Investment Advisory first reported a position in ALNY in Q4 2022 and held it in 4 quarters. The position peaked at $3.09K in Q4 2022. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

Cary Street Partners Investment Advisory reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 13 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $2.3K.
Cary Street Partners Investment Advisory first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 4 quarters.
Cary Street Partners Investment Advisory's Alnylam Pharmaceuticals position peaked at $3.09K in Q4 2022.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.